During the year, Enzymatica’s Board of Directors held 15 meetings at which the minutes were recorded, 4 of which were by telephone and 4 per capsulam. Four of the meetings were held in conjunction with approval of the year-end report and the interim reports. Important matters addressed during the year included strategy, growth issues, COVID-19, funding, organization, adoption of the budget and regulatory matters, such as how the company will address the new EU Medical Device Regulation. The CEO, CFO and COO of the company regularly participate at the Board meetings. Other senior executives participate at Board meetings as needed. The company’s auditor attends at least one regular meeting during the year.